Plantar heel pain touches 10% to 15% of adults at any given time, and about 20% of people experience it on both sides. Yet what drives costs, imaging choices, and treatment rankings is not just prevalence but how outcomes are measured, how long symptoms persist, and whether conservative care keeps patients out of procedures. In this post, we connect those threads with the latest evidence on everything from ESWT and night splints to PRP and foot orthosis use.
Key Takeaways
- In economic evaluations, the incremental cost-effectiveness of conservative interventions depends on time horizon and health-state utilities; plantar fasciitis is modeled as a pain condition in cost-effectiveness frameworks
- Imaging use (ultrasound/MRI) impacts total costs; ultrasound is lower-cost than MRI in typical healthcare pricing structures
- Botulinum toxin injection cost and limited payer coverage can affect overall cost-effectiveness; trials report pain outcomes allowing economic modeling
- 10% lifetime risk of developing plantar fasciitis
- 10%–15% of adults have plantar heel pain at any given time, reflecting the period prevalence of heel pain/plantar fasciitis–type symptoms in adults
- Systematic reviews commonly report plantar fasciitis as the most common cause of inferior heel pain
- Surgery rates remain low because most patients improve with conservative care, shaping payer and provider trends toward nonoperative protocols
- Clinical trials use standardized outcome measures such as pain VAS and foot function scores to compare emerging treatments
- Night splints are a continuing innovation area in conservative care; RCTs quantify functional improvements versus control groups
- MRI can detect plantar fascia thickening and perifascial edema in plantar fasciitis
- Complication rates after plantar fascia release surgery are uncommon, with major complications reported in low single-digit percentages in surgical case series
- Conservative treatments often reduce pain sufficiently to return to normal walking activities within months for many patients
- The UK NHS provides a publicly accessible heel pain overview used to guide diagnosis and management for plantar fasciitis-related presentations
- In the US, foot orthotics and brace markets are multi-billion-dollar categories; plantar-fasciitis-related orthoses are a substantial segment of orthotic demand (US market sizing context)
- In a US dataset, plantar fasciitis/heel pain is frequently coded among lower-extremity musculoskeletal diagnoses driving podiatry and orthopedics outpatient utilization
About 10 percent of adults get plantar heel pain, and most improve with conservative, low cost care.
Related reading
01 · Category
Cost Analysis6 stats
01
In economic evaluations, the incremental cost-effectiveness of conservative interventions depends on time horizon and health-state utilities; plantar fasciitis is modeled as a pain condition in cost-effectiveness frameworks
02
Imaging use (ultrasound/MRI) impacts total costs; ultrasound is lower-cost than MRI in typical healthcare pricing structures
03
Botulinum toxin injection cost and limited payer coverage can affect overall cost-effectiveness; trials report pain outcomes allowing economic modeling
04
Sustained recurrence risk can increase cumulative costs; observational studies track repeat episodes over time
05
Foot orthotics market is valued at tens of billions globally in industry sizing reports, indicating high expenditure on orthotic support for conditions including plantar fasciitis
06
AHRQ HCUP databases contain standardized national cost estimates by diagnosis-related groups and outpatient settings used in economic comparisons for MSK conditions
Interpretation
Cost Analysis Interpretation
From a cost analysis perspective, total costs are strongly driven by the care pathway, especially imaging where ultrasound is typically lower cost than MRI, and recurrence over time can raise cumulative spending even though payer coverage and the cost of botulinum toxin may limit overall cost effectiveness.
02 · Category
Epidemiology5 stats
01
10% lifetime risk of developing plantar fasciitis
02
10%–15% of adults have plantar heel pain at any given time, reflecting the period prevalence of heel pain/plantar fasciitis–type symptoms in adults
03
Systematic reviews commonly report plantar fasciitis as the most common cause of inferior heel pain
04
Approximately 20% of patients with plantar fasciitis have bilateral symptoms
05
Treadmill/in-shoe pressure studies show plantar fasciitis is associated with altered plantar pressure distribution, with pressure differences across symptomatic vs. asymptomatic feet commonly exceeding 10% in gait analyses
Interpretation
Epidemiology Interpretation
From an epidemiology standpoint, plantar fasciitis affects about 10% of people over their lifetime and around 10% to 15% of adults at any given time, making it the most common cause of inferior heel pain with roughly one in five cases showing bilateral symptoms.
03 · Category
Industry Trends12 stats
01
Surgery rates remain low because most patients improve with conservative care, shaping payer and provider trends toward nonoperative protocols
02
Clinical trials use standardized outcome measures such as pain VAS and foot function scores to compare emerging treatments
03
Night splints are a continuing innovation area in conservative care; RCTs quantify functional improvements versus control groups
04
A 2015 network meta-analysis used multiple direct and indirect comparisons to rank interventions by pain reduction effect sizes
05
In a Cochrane review, patient-reported outcomes are summarized across trials to estimate overall effects of shockwave and other modalities
06
Foot orthosis adherence and fit quality are increasingly monitored as measurable factors influencing outcomes in outpatient care pathways
07
Telehealth and digital symptom monitoring are increasingly used for musculoskeletal pain follow-up; clinical trials commonly report functional and pain outcomes collected over time
08
PRP utilization is growing as an outpatient regenerative option; meta-analyses compile measurable pain/function outcomes to assess adoption rationale
09
Functional improvements measured by foot function scales are used to evaluate orthotics, stretching, and adjunctive therapies
10
Orthotics market demand is driven by musculoskeletal foot conditions, including plantar fasciitis, as reflected in market sizing reports
11
Industry reports track increasing adoption of shockwave therapy devices in outpatient settings for plantar fasciitis among other indications
12
In US outpatient datasets (HCUP), procedure and diagnosis coding allows tracking of heel pain/plantar fasciitis care patterns over time
Interpretation
Industry Trends Interpretation
Surgery rates staying low as conservative care continues to dominate is reinforced by ongoing trial standardization with pain VAS and foot function scores plus growing outpatient adoption trends like shockwave therapy and monitored orthosis use, all of which are tracked through US datasets such as HCUP coding.
04 · Category
Diagnostics & Imaging1 stats
01
MRI can detect plantar fascia thickening and perifascial edema in plantar fasciitis
Interpretation
Diagnostics & Imaging Interpretation
MRI provides a clear diagnostic signal for plantar fasciitis by detecting plantar fascia thickening along with perifascial edema.
05 · Category
Treatments & Outcomes2 stats
01
Complication rates after plantar fascia release surgery are uncommon, with major complications reported in low single-digit percentages in surgical case series
02
Conservative treatments often reduce pain sufficiently to return to normal walking activities within months for many patients
Interpretation
Treatments & Outcomes Interpretation
In the Treatments and Outcomes category, most patients improve with conservative care within a few months to resume normal walking, and when surgery is needed major complications are uncommon with low single-digit rates reported in case series.
06 · Category
Market Size3 stats
01
The UK NHS provides a publicly accessible heel pain overview used to guide diagnosis and management for plantar fasciitis-related presentations
02
In the US, foot orthotics and brace markets are multi-billion-dollar categories; plantar-fasciitis-related orthoses are a substantial segment of orthotic demand (US market sizing context)
03
In a US dataset, plantar fasciitis/heel pain is frequently coded among lower-extremity musculoskeletal diagnoses driving podiatry and orthopedics outpatient utilization
Interpretation
Market Size Interpretation
Across both the UK NHS guidance and US outpatient coding patterns, plantar fasciitis and heel pain are clearly substantial enough to support large, multi-billion-dollar orthotics and brace market segments, indicating meaningful market size driven by frequent real-world demand.
More related reading
07 · Category
Burden & Access3 stats
01
33.5% of US adults reported chronic pain in 2019 (self-reported), providing context for how plantar-fasciitis pain often co-occurs with broader musculoskeletal pain burden
02
In the US, office-based visits for plantar fasciitis/heel pain are disproportionately higher among adults with obesity, with odds ratios in observational analyses typically above 1.0 for obesity-related risk
03
In a large observational cohort, patients who received an orthosis-based conservative program had lower subsequent procedural rates, with reductions on the order of several percentage points versus non-orthosis pathways
Interpretation
Burden & Access Interpretation
From a burden and access perspective, plantar fasciitis sits within a wider pain landscape where 33.5% of US adults reported chronic pain in 2019, and the need for care appears amplified by obesity with observational odds ratios above 1.0, while access to effective conservative options like orthosis-based programs may help lower follow-on procedural use by several percentage points.
08 · Category
Treatment Outcomes7 stats
01
A 2018 systematic review found extracorporeal shockwave therapy (ESWT) improved pain and function versus control in multiple trials, with pooled effects producing statistically significant differences
02
A 2020 meta-analysis reported that ESWT yields clinically meaningful improvements in pain scores (e.g., VAS) compared with placebo/sham, with effect sizes typically in the moderate range (around 0.5 standardized mean difference)
03
A 2021 meta-analysis found that combining stretching with other conservative modalities improves plantar-fasciitis pain more than stretching alone in pooled analyses
04
A randomized trial of plantar fasciitis taping reported statistically significant improvements in foot pain and function at follow-up compared with control, with between-group differences reaching clinically relevant thresholds (e.g., single-digit points on common foot function scales)
05
A 2019 meta-analysis reported that night splints improve pain/function compared with no splint or minimal intervention, with pooled mean differences favoring splinting
06
A randomized controlled trial found that weight-loss plus exercise for overweight participants with plantar fasciitis led to greater improvements in pain/function than exercise alone, with between-group differences measured in weeks-to-months time frames and statistically significant post-treatment outcomes
07
Botulinum toxin injection trials report pain improvement over placebo/sham in follow-up windows typically centered around 2–12 weeks, with between-group differences reaching statistical significance in pooled analyses
Interpretation
Treatment Outcomes Interpretation
Overall, across treatment outcomes studies ESWT shows statistically and clinically meaningful improvements with moderate effect sizes around 0.5 standardized mean difference, while other conservative add ons like stretching combinations, night splints, and taping also outperform their comparators in pooled analyses and trials.
09 · Category
Imaging & Diagnostics1 stats
01
Ultrasound-guided approaches can reduce uncertainty in injection placement; studies in musculoskeletal injection practice report higher accuracy rates (often >90%) for ultrasound-guided needle positioning compared with landmark-based methods
Interpretation
Imaging & Diagnostics Interpretation
In the Imaging & Diagnostics category, ultrasound-guided approaches can markedly improve precision, with studies reporting ultrasound needle positioning accuracy often above 90% versus less reliable landmark-based placement, helping reduce uncertainty during plantar fasciitis injections.
10 · Category
Cost & Utilization1 stats
01
In a US claims-based analysis of outpatient MSK imaging utilization, MRI is markedly more costly than ultrasound for extremity indications, with typical ratio differences exceeding 2x in allowed amounts
Interpretation
Cost & Utilization Interpretation
In a US outpatient MSK imaging utilization analysis, MRI was more costly than ultrasound for extremity indications by more than 2x in allowed amounts, underscoring that cost differences are a key utilization driver in the Cost and Utilization category for plantar fasciitis.
11 · Category
Surgical & Safety3 stats
01
Plantar fascia release is associated with low but measurable post-operative complication rates; cohort studies commonly report major complication rates in the low single digits (e.g., 1%–3%)
02
Altered gait after plantar fascia release can be measured; studies using validated gait metrics report statistically significant changes in plantar pressure/symmetry in a minority of patients, often around ~10%–20% in those assessed
03
Recurrence or persistence of heel pain after conservative therapy can be substantial; observational follow-up studies frequently show persistent symptoms in roughly 10%–20% of patients after extended follow-up (e.g., 1 year)
Interpretation
Surgical & Safety Interpretation
For Surgical & Safety, the evidence suggests that plantar fascia release generally stays relatively safe with major complications typically around 1% to 3%, yet meaningful post-surgical functional or symptom issues still show up for a minority of patients, with altered gait reported in about 10% to 20% and persistent or recurrent heel pain after extended follow-up in roughly 10% to 20%.
12 · Category
Market & Industry2 stats
01
The global orthotics/prosthetics market is valued in the tens of billions of US dollars; foot orthoses and braces represent a major segment of that market for lower-extremity musculoskeletal support
02
PRP market forecasts indicate multi-billion-dollar growth by 2030 driven by orthopedic and musculoskeletal indications, including soft-tissue pain conditions such as plantar fasciitis
Interpretation
Market & Industry Interpretation
The market outlook for Plantar Fasciitis is strengthening as foot orthoses and braces already make up a major share of the tens of billions global orthotics and prosthetics market, while PRP is projected to reach multi billion dollar growth by 2030, driven by orthopedic and musculoskeletal use cases including soft tissue pain like plantar fasciitis.
Reference
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
APA
Karl Becker. (2026, February 13). Plantar Fasciitis Statistics. Gitnux. https://gitnux.org/plantar-fasciitis-statistics
MLA
Karl Becker. "Plantar Fasciitis Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/plantar-fasciitis-statistics.
Chicago
Karl Becker. 2026. "Plantar Fasciitis Statistics." Gitnux. https://gitnux.org/plantar-fasciitis-statistics.
Sources & references
46 datasets cited across this report · attribution is report-level
+26 additional datasets cited (not shown individually)